Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
John W OstrominskiMuthiah VaduganathanSenthil SelvarajBrian Lee ClaggettZi Michael MiaoAkshay S DesaiPardeep S JhundMikhail Naum KosiborodCarolyn Su Ping LamCatherine M ViscoliFelipe A MartinezRudolf A de BoerAdrian F HernandezSanjiv J ShahMagnus PeterssonAnna Maria LangkildeJohn Joseph Valentine McMurrayScott D SolomonPublished in: Circulation (2023)
gov; Unique identifier: NCT03619213.
Keyphrases
- ejection fraction
- heart failure
- aortic stenosis
- blood pressure
- phase iii
- study protocol
- phase ii
- clinical trial
- diffusion weighted imaging
- left ventricular
- acute heart failure
- cardiac resynchronization therapy
- atrial fibrillation
- open label
- randomized controlled trial
- transcatheter aortic valve replacement
- aortic valve
- arterial hypertension